Literature DB >> 9614826

Unconventional therapies for cancer: 4. Hydrazine sulfate. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

E Kaegi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9614826      PMCID： PMC1229327     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  49 in total

1.  Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy.

Authors:  J Gold
Journal:  Oncology       Date:  1974       Impact factor: 2.935

2.  Inhibition by hydrazine sulfate and various hydrazides, of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia.

Authors:  J Gold
Journal:  Oncology       Date:  1973       Impact factor: 2.935

3.  Hydrazine, methylhydrazine and methylhydrazine sulfate carcinogenesis in Swiss mice. Failure of ammonium hydroxide to interfere in the development of tumors.

Authors:  B Toth
Journal:  Int J Cancer       Date:  1972-01-15       Impact factor: 7.396

4.  Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate.

Authors:  J Gold
Journal:  Oncology       Date:  1971       Impact factor: 2.935

5.  Proposed treatment of cancer by inhibition of gluconeogenesis.

Authors:  J Gold
Journal:  Oncology       Date:  1968       Impact factor: 2.935

6.  Inhibition of Walker 256 intramuscular carcinoma in rats by administration of L-tryptophan.

Authors:  J Gold
Journal:  Oncology       Date:  1970       Impact factor: 2.935

7.  Trial of hydrazine sulfate (NSC-150014) in patients with cancer.

Authors:  M Ochoa; R E Wittes; I H Krakoff
Journal:  Cancer Chemother Rep       Date:  1975 Nov-Dec

8.  Paths of carbon in gluconeogenesis and lipogenesis. IV. Inhibition by L-tryptophan of hepatic gluconeogenesis at the level of phosphoenolpyruvate formation.

Authors:  P D Ray; D O Foster; H A Lardy
Journal:  J Biol Chem       Date:  1966-09-10       Impact factor: 5.157

9.  Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients.

Authors:  J Gold
Journal:  Oncology       Date:  1975       Impact factor: 2.935

10.  Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in walker 256 carcinosarcoma in rats.

Authors:  J Gold
Journal:  Oncology       Date:  1975       Impact factor: 2.935
View more
  3 in total

1.  The arrogance of science and the pitfalls of hope.

Authors:  J Hoey
Journal:  CMAJ       Date:  1998-10-06       Impact factor: 8.262

2.  Key role of hydrazine to the interaction between oxaloacetic against phosphoenolpyruvic carboxykinase (PEPCK): ONIOM calculations.

Authors:  Pongthep Prajongtat; Darinee Sae-Tang Phromyothin; Supa Hannongbua
Journal:  J Mol Model       Date:  2013-04-27       Impact factor: 1.810

Review 3.  Cancer cachexia--pathophysiology and management.

Authors:  Hajime Suzuki; Akihiro Asakawa; Haruka Amitani; Norifumi Nakamura; Akio Inui
Journal:  J Gastroenterol       Date:  2013-03-20       Impact factor: 7.527
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.